NCT04893759 2025-04-17A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsAscentage Pharma Group Inc.Phase 1 Terminated2 enrolled
NCT04210037 2022-07-12Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerAscentage Pharma Group Inc.Phase 1/2 Terminated28 enrolled
NCT03387332 2021-08-27APG-1252 in Patients With SCLC or Advanced Solid TumorsAscentage Pharma Group Inc.Phase 1 Terminated24 enrolled